Our science

Modifying Disease Progression Through Cell Repair and Restoration

AVIPERO Bio was founded by core scientific expertise with a keen interest in therapeutic disruptors in clinical indications where treatments stagnated due to misunderstood pathologies. Our target was cellular repair.

AVIPERO Bio seeks to reimagine beta1 integrin targeting in oncology by deconvoluting its role in cancer cell behaviour.  In irreversible injury and senescence models, AVIPERO identified beta1 integrin as a novel target for inducing repair and regeneration and reversing aging. Targeting the non-ligand binding part of beta1 integrin to allosterically preserve the receptor in its normal low affinity state (dimmer switch), reduces matrix stiffness and cellular stress and normalises cell cycle to allow normal aging.

Beta1 Integrin is crucial for tumor metastasis and increased expression is associated with decreased survival advanced cancers. Ablation of beta1 integrin
in tumor cells reduces tumor cell proliferation and the acquisition of
cellular aging.

Antibodies against beta1-integrin inhibited tumour growth in mouse models of breast cancer, prostate cancer, osteosarcoma and melanoma. Anti-beta1 integrin antibody inhibits metastasis of breast cancer.

Metastatic Cancer is a severe unmet medical need

The Global cancer metastases clinical pipeline stands at 66 drugs with 14 currently marketed.


The Biological and Pharmacological mechanism of action of beta1 integrin-mediated repair


The epitope location of AVI001 determines the Pharmacological mode of action